Sponsored By

Here’s How Pfizer Is Boldly Moving into Digital Health

The company is set to acquire Resapp Health, a company that develops smartphone applications for the diagnosis and management of respiratory disease.

Omar Ford

April 14, 2022

1 Min Read
IMG_2022-4-13-101622.jpg
Image courtesy of Kristoffer Tripplaar / Alamy Stock Photo

Pharmaceutical companies are diving deeper into digital health. Earlier this week, Pfizer said it would acquire Resapp Health Ltd, a company that develops smartphone applications for the diagnosis and management of respiratory disease.

The deal would be for $74 million, and Pfizer would acquire Resapp Health through its Australian subsidiary.

Resapp has developed ResAppDx and SleepCheck, which have CE mark and Therapeutic Goods Administration (TGA) approved in Australia.

But the attraction to Resapp could be because the company recently reported strong results from clinical trials of its new COVID-19 instant screening test. The application uses a smartphone and cough sounds to detect the presence of infection.

Pharmaceutical companies jumping into digital health isn’t a new thing and was a trend even before the pandemic began.

In September of 2019, Bayer formed a licensing agreement with OneDrop, a developer of digital therapeutic solutions for diabetes and other chronic solutions.

Under the partnership, One Drop's platform was used in Bayer's bio-digital efforts in therapeutic areas such as oncology, cardiovascular disease, and women's health. 

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like